DLBCL Responds Well to Anti-CD19 CAR Therapy.
According to an interim analysis of phase II data from a study of the anti-CD19 chimeric antigen receptor T-cell therapy KTE-C19, 76% of 51 patients with diffuse large B-cell lymphoma responded to the treatment; 47% had a complete response. After 3 months, 33% continued to experience a complete response.
D018941:Antigens, CD19 / Q000378:metabolism; D017322:Clinical Trials, Phase II as Topic; D006801:Humans; D016403:Lymphoma, Large B-Cell, Diffuse / Q000378:metabolism / Q000628:therapy*; D015337:Multicenter Studies as Topic; D013601:T-Lymphocytes / Q000378:metabolism / Q000637:transplantation*; D016896:Treatment Outcome
D018941:Antigens, CD19; C000604811:CD19 molecule, human